Metformin superior to low-fat diet for the treatment of patients with nonalcoholic fatty liver disease and/or steatohepatitis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue SUPPL.1, 2012, Pages 68-71

  Resuli, Bashkim ^a   Demiraj, Vigjilenca ^a   Babameto, Adriana ^a   Sema, Klara ^a   Malaj, Valdete ^a  

^a University Service of Gastroenterology and Hepatology   (Albania)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY WEIGHT; DRUG EFFICACY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY;

EID: 84872813025     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1505     Document Type: Article

References (41)

1. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med. 1979; 67: 811-816.
2. Ludwig J, Viggiano TR, McGill BD, Oh BJ. Nonalcoholic steatohepatitis: Mayo clinic experience with an hitherto unnamed disease. Mayo Clin Prac. 1980; 55: 434-435.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231.
4. Mulcahy N. Type 2 diabetes, high ALT levels boot risk of NASH. Int Med News. 2003; April 15.
5. Caldwell SH, Crespo AM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004; 127 (Suppl 1): 97-103.
6. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002; 123: 134-140.
7. Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009; 44 (Suppl 19): 89-95.
8. Tokushige K, Hashimoto E, Yatsuji S, et al. Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol. 2010; 45: 960-967.
9. Kowdley KV, Caldwell S. Nonalcoholic steatohepatitis: a twenty-first century epidemic. J Clin Gastroenterol. 2006; 40 (Suppl 1): 2-4.
10. de Alvis NM, Day CP Non-alcoholic fatty liver disease: The mist gradually clears. J Hepatol. 2008; 48 (Suppl 1): 104-112.
11. World Health Organisation (WHO). The World Health Report 1998. Life in the 21th century - a vision for all. Geneva: WHO 1998.
12. Shapo L, Pomerleau J, McKee M, et al. Body weight patterns in a country of transition: a population-based survey in Tirana City, Albania. Public Health Nutri. 2003; 6: 471-477.
13. Cheung P, Kapoor A, Puri P, et al. The impact of fat distribution on the severity of nonalcoholic disease and meta bolic syndrome. Hepatology. 2007; 46: 1091-1100.
14. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis and the meta bolic syndrome. Hepatology. 2003; 37: 917-923.
15. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatolgy. 2005; 42: 987-1000.
16. Marchesini G, Marzochi R, Natale S. NAFLD - Why not to treat the insulin resistance? In: Non-alcoholic steatohepatitis: from cell bio logy to clinical practice (Monothematic Conference of the European Association for the Study of the Liver [EASL], Estoril, Portugal, September 2004). Lisbon, 2004: 60-64.
17. Marchesini G, Brizi M, Bianchi M, et al. Nonalcoholic fatty liver disease: a feature of meta bolic syndrome. Diabetes. 2001; 50: 1844-1850.
18. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006; 40 (Suppl 1): 17-29.
19. Larter C, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J Hepatol. 2006; 44: 253-261.
20. Lee s, Park SH, Kim JH. Non invasive assessment of hepatic steatosis: Prospective comparison of the occurrence of imaging examinations. J Hepatol. 2010; 52: 579-587.
21. Saadeh S, Yonussi ZM, Remer EM, et al. The utility of radio logical imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123: 745-750.
22. Suzuki A, Lindor K, St Saver J, et al. Effects of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol. 2005; 43: 1060-1066.
23. Riley P, Sudarshi D, Johal M, et al. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract. 2008; 62: 374-381.
24. Loomba R, Lutchman G, Kleiner DE, et al. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2009; 29: 172-182.
25. Nair S, Diehl AM, Wiseman M, et al. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004; 20: 23-28.
26. Schwimmer JB, Middleton MS, Deutch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic pediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005; 21: 871-879.
27. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004; 39: 188-196.
28. Sanyal AJ, Mofrad PS, Contos MJ, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2004; 2: 1107-1115.
29. Belford R, Harrison RA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297-2307.
30. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005; 100: 1082-1090.
31. Huang MA, Greenson JK, Chao C, et al. One-year intense nutritional counseling results in histo logical improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol. 2005, 100: 1072-1081.
32. Osland JE, Powel ER, Banks M, et al. Obesity management in liver clinics: translation of research into clinical practice. J Gastroenterol Hepatol. 2007; 22: 504-509.
33. Ballentani S, Delle Grave R, Suppini A, et al. Fatty Liver Italian Network. Behaviour therapy for nonalcoholic fatty liver disease: the need for multidisciplinary approach. Hepatology. 2008; 47: 746-754.
34. Chan HL, de Silva HJ, Leung NW et al. Asia-Pacific Working Party on NAFLD. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol. 2007; 22: 801-808.
35. de Piano A, Prado WL, Caranti DA, et al. Metabolic and nutritional profile of obese adolescents with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2007; 44: 446-452.
36. Caldwell Sh, Hespenheide EE, Redick JA, et al. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001; 96: 519-525.
37. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligands rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol. 2003; 38: 434-440.
38. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000; 6: 998-1003.
39. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet. 2001; 358: 893-894.
40. Uygun A, Kadryfici A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004; 19: 537-544.
41. Watt MJ, Dzamko N, Thomas WG, et al. CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med. 2006; 12: 541-548.